Skip to main content
SYK
NYSE Industrial Applications And Services

Stryker Q2 Sales Jump 9.4%, Adjusted EPS Up 17.9%; Narrows Full-Year Outlook After Cyberattack

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$324.665
Mkt Cap
$124.464B
52W Low
$281
52W High
$401.99
52W Position info
16% above low
Off High info
19% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

SYK sits 16% above its 52-week low of $281.

Summary

Stryker reported Q2 2026 net sales of $6.59B (+9.4% YoY) and adjusted EPS of $3.69 (+17.9%), beating estimates. The company narrowed its full-year adjusted EPS guidance, citing the March 2026 cyberattack impact, and completed the AVS acquisition.


Key Events · Earnings and Guidance · SYK

  • Q2 Sales and Earnings Beat

    Net sales rose 9.4% to $6.59B; adjusted EPS of $3.69 beat the $3.49 consensus, up 17.9% YoY.

  • Full-Year Guidance Narrowed

    Stryker narrowed its full-year adjusted EPS outlook, explicitly linking the revision to the March 2026 cyberattack that disrupted operations.

  • Gross Margin Expansion

    Gross margin improved to 68.3% from 63.8%, driven by a $158M reversal of 2025 tariffs and lower acquisition-related inventory charges.

  • AVS Acquisition Completed

    Acquired Amplitude Vascular Systems for $435M net cash plus up to $400M in milestones, adding a next-gen intravascular lithotripsy platform.


Analysis · SYK · Industrial Applications And Services

A strong second quarter saw net sales climb 9.4% to $6.59 billion and adjusted earnings per share surge 17.9% to $3.69, handily beating consensus estimates. The company narrowed its full-year adjusted EPS guidance, explicitly attributing the revision to the lingering impact of a March 2026 cyberattack that disrupted operations. Gross margin expanded sharply, helped by a $158 million reversal of 2025 tariffs and lower acquisition-related inventory charges. The quarter also included the completion of the AVS acquisition for $435 million in cash plus up to $400 million in milestone payments, adding a next-generation intravascular lithotripsy platform to its peripheral vascular portfolio. While the results and guidance update are positive, the cyberattack's ongoing effect and the narrowed outlook introduce some uncertainty.

At the time of this filing, SYK was trading at $324.67 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $124.5B. The 52-week trading range was $281.00 to $401.99. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SYK - Latest Insights

SYK
Jul 30, 2026, 8:14 PM EDT
Source: Binance News
Importance Score:
7
Price at Filing: $321.06
Real-time Price: $324.64 info
Change: +$3.58 (+1%) info
Market Cap: $124.454B info
SYK
Jul 30, 2026, 4:31 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $316.00
Real-time Price: $324.64 info
Change: +$8.64 (+3%) info
Market Cap: $124.454B info
SYK
Jul 30, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $318.00
Real-time Price: $324.64 info
Change: +$6.64 (+2%) info
Market Cap: $124.454B info
SYK
May 27, 2026, 8:49 AM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $316.40
Real-time Price: $324.64 info
Change: +$8.24 (+3%) info
Market Cap: $124.454B info
SYK
May 19, 2026, 5:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $307.70
Real-time Price: $324.64 info
Change: +$16.94 (+6%) info
Market Cap: $124.454B info